Nuveen
COGT icon

Nuveen’s Cogent Biosciences COGT Stock Holding History

Nuveen’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.5M Sell
657,664
-173,938
-21% -$6.09M 0.01% 1109
2026
Q1 		$32M Sell
831,602
-101,019
-11% -$3.73M 0.01% 873
2025
Q4 		$33.1M Sell
932,621
-6,999
-0.7% -$197K 0.01% 849
2025
Q3 		$13.5M Buy
939,620
+709,508
+308% +$8.41M ﹤0.01% 1382
2025
Q2 		$1.65M Sell
230,112
-3,740
-2% -$20.7K ﹤0.01% 2387
2025
Q1 		$1.4M Sell
233,852
-79,247
-25% -$621K ﹤0.01% 2484
2024
Q4 		$2.44M Sell
313,099
-1,896
-0.6% -$18.9K ﹤0.01% 2291
2024
Q3 		$3.4M Sell
314,995
-449,352
-59% -$4.38M ﹤0.01% 2171
2024
Q2 		$6.44M Sell
764,347
-257,744
-25% -$1.95M ﹤0.01% 1820
2024
Q1 		$6.87M Buy
1,022,091
+777,343
+318% +$4.81M ﹤0.01% 1813
2023
Q4 		$1.44M Buy
244,748
+23,371
+11% +$179K ﹤0.01% 2569
2023
Q3 		$2.16M Sell
221,377
-32,551
-13% -$386K ﹤0.01% 2270
2023
Q2 		$3.01M Buy
253,928
+14,842
+6% +$170K ﹤0.01% 2163
2023
Q1 		$2.58M Buy
239,086
+20,902
+10% +$267K ﹤0.01% 2236
2022
Q4 		$1.08M Sell
218,184
-460,863
-68% -$5.71M ﹤0.01% 2653
2022
Q3 		$3.37M Buy
679,047
+480,816
+243% +$6.59M ﹤0.01% 2122
2022
Q2 		$983K Buy
198,231
+83,583
+73% +$570K ﹤0.01% 2785
2022
Q1 		$780K Sell
114,648
-1,959
-2% -$13.6K ﹤0.01% 2892
2021
Q4 		$926K Sell
116,607
-9,458
-8% -$82.2K ﹤0.01% 2886
2021
Q3 		$1.13M Sell
126,065
-3,785
-3% -$29K ﹤0.01% 2947
2021
Q2 		$1.05M Buy
+129,850
New +$1.1M ﹤0.01% 2986

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen's COGT Position: Q2 2026 in Review

Nuveen reduced its Cogent Biosciences (COGT) stake by 21% in Q2 2026, selling an estimated $6.09M and leaving 657,664 shares worth $25.5M. The position accounts for 0.01% of the portfolio, ranked #1109.

Nuveen first reported a position in COGT in Q2 2021 and has held it in 21 quarters since. The position peaked at $33.1M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Nuveen held 657,664 shares of Cogent Biosciences worth $25.5M as of Q2 2026.
  • Nuveen sold 173,938 Cogent Biosciences shares in Q2 2026, an estimated $6.09M.
  • Cogent Biosciences made up 0.01% of Nuveen's portfolio in Q2 2026, its #1109 holding.
  • Nuveen first reported a position in Cogent Biosciences in Q2 2021 and has held it in 21 quarters since.
  • Nuveen's Cogent Biosciences position peaked at $33.1M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.